Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic

Bruton tyrosine kinase inhibitors (BTKis) encompass a new class of therapeutics currently being evaluated for the treatment of multiple sclerosis (MS). Whether BTKis affect COVID-19 risk or severity or reduce vaccine efficacy are important but unanswered questions. Here, we provide an overview on BT...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Martin S., Nicholas, Jacqueline A., Yeaman, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Views & Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428017/
https://www.ncbi.nlm.nih.gov/pubmed/34497100
http://dx.doi.org/10.1212/NXI.0000000000001067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428017/
https://www.ncbi.nlm.nih.gov/pubmed/34497100
http://dx.doi.org/10.1212/NXI.0000000000001067

Ejemplares similares